

Advent Pharma Ltd.
Statement of Financial Position (Un-audited)
As at December 31, 2021

Particulars	Notes	Amount in Taka	
		31-Dec-2021	30-Jun-2021
ASSETS			
NON-CURRENT ASSETS		1,347,494,004	1,257,626,287
Property, Plant & Equipment	4.00	1,207,888,378	1,227,902,159
Capital Work in Progress (Building Construction)	5.00	139,605,626	29,724,128
Right of use Assets		145,708	437,124
CURRENT ASSETS		245,391,965	261,979,334
Inventories	6.00	77,195,910	75,411,909
Trade and Other Receivable		116,921,563	114,021,998
Advances, Deposits and Pre-payments		33,976,967	29,856,397
Investment in FDR	7.00	-	40,000,000
Cash and Cash Equivalents	8.00	17,297,525	2,689,030
Total Assets		1,593,031,677	1,520,042,745
SHAREHOLDERS' EQUITY AND LIABILITIES			
SHAREHOLDERS' EQUITY		1,278,345,757	1,234,180,120
Share Capital	9.00	913,066,000	913,066,000
Retained Earnings	10.00	365,279,757	321,114,120
NON-CURRENT LIABILITIES		136,256,636	133,550,170
Long Term Borrowings - Net of Current Portion		12,701,026	14,561,946
Deferred Tax Liabilities	11.00	123,555,610	118,988,224
Liabilities for lease net current maturity	14.00	-	-
CURRENT LIABILITIES		178,429,284	152,312,455
Current Portion of Long Term Borrowings		7,912,963	7,912,963
Payable to IPO Applicants		109,355	109,355
Short Term Borrowings		38,213,344	36,826,566
Trade and other payables		4,157,602	8,917,226
Unclaimed Dividend Account	12.00	3,356,288	6,550,487
Dividend Payable	13.00	18,261,320	-
Liabilities for Lease-current maturity	14.00	284,106	607,545
Liabilities for expenses		3,876,173	8,468,549
Liability for contribution to WPPF		36,290,560	30,508,761
Provision for Current Tax	15.00	65,967,572	52,411,003
Total Liabilities		314,685,920	285,862,625
Total Shareholders' Equity and Liabilities		1,593,031,677	1,520,042,745
Net Asset Value (NAV) per Share	23.00	14.00	13.52


Company Secretary


Chief Financial Officer


Director


Managing Director


Chairman

Dated: January 30, 2022
Place: Dhaka

Advent Pharma Ltd.
Statement of Profit or Loss and Other Comprehensive Income (Un-audited)
For the Period from July 01, 2021 to December 31, 2021

Particulars	Notes	Amount in Taka		Amount in Taka	
		July 01, 2021 to Dec. 31, 2021	July 01, 2020 to Dec. 31, 2020	Oct. 01, 2021 to Dec. 31, 2021	Oct 01, 2020 to Dec 31, 2020
A Revenues		265,507,813	261,923,050	126,172,402	131,029,645
B Cost of Sales	16.00	(149,509,179)	(137,592,547)	(73,178,959)	(64,504,358)
C Gross Profit		115,998,634	124,330,503	52,993,443	66,525,287
Operating Expenses		(29,052,637)	(20,127,739)	(15,968,965)	(9,722,746)
D Administrative expenses	18.00	(10,985,927)	(7,905,949)	(6,248,635)	(3,940,635)
Selling & Marketing Expenses	19.00	(18,066,710)	(12,221,790)	(9,720,330)	(5,782,111)
E Operating Profit		86,945,997	104,202,764	37,024,478	56,802,541
Non Operating Expenses		(3,584,761)	(3,461,227)	(1,888,681)	(1,814,552)
F Financial Expenses	20.00	(3,584,761)	(3,461,227)	(1,888,681)	(1,814,552)
G Other Income	21.00	1,217,222	1,887,192	77,712	121,545
H Profit Before W.P.P.F		84,578,458	102,628,729	35,213,509	55,109,534
I Expenses for W.P.P.F		(4,027,546)	(4,887,082)	(1,676,834)	(2,624,264)
J Profit Before Tax		80,550,913	97,741,647	33,536,676	52,485,270
K Income Tax Expenses		(18,123,956)	(25,272,743)	(7,545,752)	(13,645,379)
Current Tax	15.00	(13,556,569)	(13,966,318)	(5,261,634)	(8,006,995)
Deferred Tax	11.00	(4,567,386)	(11,306,425)	(2,284,119)	(5,638,384)
L Net Profit After Tax		62,426,957	72,468,904	25,990,923	38,839,891
M Other Comprehensive Income		-	-	-	-
N Total Comprehensive income		62,426,957	72,468,904	25,990,923	38,839,891
O Basic Earnings per Share (EPS)	22.00	0.68	0.79	0.28	0.43


Company Secretary


Chief Financial Officer


Director


Managing Director


Chairman

Dated: January 30, 2022
Place: Dhaka

Advent Pharma Ltd.
Statement of Changes in Equity (Un-audited)
For the Period from July 01, 2021 to December 31, 2021

Particulars	Ordinary Share Capital	Retained Earnings	Total
Balance as on July 01, 2021	913,066,000	321,114,120	1,234,180,120
Net Profit for the period	-	62,426,957	62,426,957
Cash Dividend (2020-2021)		(18,261,320)	(18,261,320)
Balance as on December 31, 2021	913,066,000	365,279,757	1,278,345,757

Advent Pharma Ltd.
Statement of Changes in Equity (Un-audited)
For the Period from July 01, 2020 to December 31, 2020

Particulars	Ordinary Share Capital	Retained Earnings	Total
Balance as on July 01, 2020	830,060,000	290,530,279	1,120,590,279
Net Profit for the period	-	72,468,904	72,468,904
Stock Dividend (2019-2020)	83,006,000	(83,006,000)	-
Balance as on December 31, 2020	913,066,000	279,993,183	1,193,059,183







Company Secretary Chief Financial Officer Director Managing Director Chairman

Dated: January 30, 2022
Place: Dhaka

Advent Pharma Ltd.
Statement of Cash Flows (Un-audited)
For the Period from July 01, 2021 to December 31, 2021

Particulars	Amount in Taka	
	July 01, 2021 to Dec 31, 2021	July 01, 2020 to Dec 31, 2020
A. CASH FLOWS FROM OPERATING ACTIVITIES:		
Cash Receipts from Customers & Others	263,825,470	272,920,676
Cash Paid to Suppliers	(129,366,991)	(127,171,128)
Cash paid to Employees	(21,286,665)	(17,833,350)
Cash paid to Others	(15,891,332)	(9,970,602)
Tax Paid During This period	(1,186,484)	(729,581)
Net cash generated from operating activities	96,093,998	117,216,015
B. CASH FLOWS FROM INVESTING ACTIVITIES:		
Paid for Acquisition of Property, Plant & Equipment	(339,280)	(69,220)
Paid for Capital Work -in- Progress (construction)	(112,733,998)	(116,408,177)
Investment in FDR	40,000,000	-
Net cash used for investing activities	(73,073,278)	(116,477,397)
C. CASH FLOWS FROM FINANCING ACTIVITIES:		
Net Received/Payment of Short Term Borrowings	1,386,778	10,961,223
Net Received/Payment of Long Term Borrowings	(1,860,920)	(289,000)
Financial Expenses Paid	(4,398,885)	(2,306,278)
Cash dividend paid	(3,194,199)	(7,123,896)
Lease Payment	(345,000)	(345,000)
Net cash provided by financing activities	(8,412,226)	897,049
D. Net Increase/(Decrease) in Cash & Cash equivalents (A+B+C)	14,608,495	1,635,667
E. Cash & Cash equivalents at the beginning of the period	2,689,030	6,338,662
F. Cash & Cash equivalents at the end of the period (D+E)	17,297,525	7,974,329
G. Net Operating Cash Flow Per Share	1.05	1.28

 Company Secretary	 Chief Financial Officer	 Director	 Managing Director	 Chairman
--	--	---	---	---

Dated: January 30, 2022
 Place: Dhaka

Advent Pharma Limited

**Notes, comprising a summary of significant accounting policies and other explanatory information
as at and for the period ended 31 December-2021**

1.00 Corporate History of the Reporting Entity

Advent Pharma Limited (The Company) was incorporated in Bangladesh as a Private Limited Company under The Companies Act, 1994 vide Registration No. C-65459(2951)/2007 dated 25th January, 2007. Subsequently the company was converted into Public Company Limited by share 07 May 2016.

The registered office of the company and the factory is located at Plot # B50-54, BSCIC Industrial Estate, Dhanrai, Dhaka, Bangladesh.

2.00 Corporate Business

The Company is a Pharmaceutical company which is engaged in manufacturing, importing and marketing of animal health care drugs, nutritional supplements and feed additives for livestock like powder, bolus and liquid dosage forms. All products have duly been approved by Drug Administration Authority and Department of Live Stock respectively.

3.00 Basis of preparation and significant accounting policies

The financial statements of the company have been prepared on going concern assumption under historical cost convention, on accrual basis and in accordance with the International Accounting Standards (IASs), International Financial Reporting Standards (IFRSs), the Companies Act 1994, the Securities Exchange Rules 2020, the requirements of Financial Reporting Act 2015, Value Added Tax and Supplementary Duty Act 2012, Income Tax Ordinance 1984 and other laws and regulations applicable for the company.

The following International Accounting Standards were applied for the preparation of the financial statements for the period.

IAS 1	Presentation of Financial Statements
IAS 2	Inventories
IAS 7	Statement of Cash Flows
IAS 8	Accounting Policies, Changes in Accounting Estimates and Errors
IAS 10	Events after the Reporting Period
IAS 12	Income Taxes
IAS 16	Property, Plant & Equipment
IAS 19	Employee Benefits
IAS 23	Borrowing Costs
IAS 24	Related Party Disclosures
IAS 32	Financial Instruments: Presentation
IAS 33	Earnings per Share
IAS 34	Interim Financial Reporting
IAS 36	Impairment of Assets
IAS 37	Provisions, Contingent Liabilities and Contingent Assets
IFRS 7	Financial Instruments: Disclosures
IFRS 8	Operating Segments
IFRS 9	Financial Instruments
IFRS 15	Revenue from Contracts form Customers
IFRS 16	Leases



4.00 Property, Plant and Equipment

A Cost

Opening Balance

Add: Addition during the period

Less: Disposal during the period

B Accumulated Depreciation

Opening Balance

Add: Depreciation charged during the period

Less: Adjustment during the period

Written down Value (A-B)

Details are shown in Annexure-A.

Amount in Taka	
31-Dec-2021	30-Jun-2021
1,381,013,653	1,214,404,201
110,430	168,088,026
-	(1,478,574)
1,381,124,083	1,381,013,653
153,111,494	115,803,056
20,124,211	38,168,564
-	(860,126)
173,235,705	153,111,494
1,207,888,378	1,227,902,159

5.00 Capital Work In Progress (Building Construction)

Opening Balance

Addition during the period

Transfer to Factory Building

Closing Balance

29,724,128	5,924,163
109,881,498	190,117,421
-	(166,317,456)
139,605,626	29,724,128

6.00 Inventories

Finished Goods (Note-15.00)

Raw Materials

Packing Materials

Spare Parts

Work In Process (Note-15.00)

Total

36,527,450	32,626,808
25,958,960	25,746,190
5,596,330	6,430,426
105,345	84,135
9,007,825	10,524,350
77,195,910	75,411,909

7.00 Investment in FDR

Name of Financial Institution

Midland Bank Ltd

FDR No. 0019761

Total

-	40,000,000
-	40,000,000

8.00 Cash & Cash Equivalents

Cash in hand (Note-8.01)

Cash at bank (Note-8.02)

Total

101,346	356,016
17,196,179	2,333,014
17,297,525	2,689,030

8.01 Cash in Hand

Head Office

Depots

62,844	304,744
38,502	51,272
101,346	356,016

Cash in hand has been certified by the management of the company.

8.02 Cash at Bank (Note -8.02.01)

8.02.01 Cash at Bank

Bank Name

Islami Bank Bangladesh Ltd.

A/C No # 283517

Dutch Bangla Bank Ltd.

A/C No # 129775

Janata Bank Ltd.

A/C No # 10035785

IFIC Bank Ltd.

A/C No # 327-041

IFIC Bank Ltd.

A/C No # 327-001

IFIC Bank Ltd.

A/C No # 327-003

Shahjalal Islami Bank Ltd.

A/C No # 000-7339

Midland Bank Ltd.

A/C No # 000-6230

BRAC Bank Ltd.

A/C No # 150001

BRAC Bank Ltd.

A/C No # 150002

Total

17,196,179	2,333,014
2,649,432	245,707
222,106	1,597,505
144,741	101,998
12,660,097	65,053
108,831	49,212
1,007,953	56,475
133,619	18,545
89,345	18,574
96,083	95,973
83,972	83,972
17,196,179	2,333,014

9.00 Share Capital

Authorized Capital :

100,000,000 ordinary shares of Tk. 10.00 each

Issued, Subscribed & Paid-up Capital :

91,306,000 ordinary shares of Tk. 10.00 each

1,000,000,000	1,000,000,000
913,066,000	913,066,000



Share holding position of Shareholders:

Category of Shareholders	Number of Share Holding		Percentage of Share Holding		Amount in Taka	
	31-Dec-2021	30-Jun-2021	31-Dec-2021	#####	31-Dec-2021	30-Jun-2021
Director & Sponsor	27,409,512	28,706,342	30.02%	31.44%	274,095,120	287,063,420
Institutional	13,844,283	17,225,306	15.16%	18.87%	138,442,830	172,253,060
Public	50,052,805	45,374,952	54.82%	49.70%	500,528,050	453,749,520
Total	91,306,600	91,306,600	100.00%	100.00%	913,066,000	913,066,000

10.00 Retained Earnings		
Balance brought forward	321,114,120	290,530,279
Add: Profit for the period	62,426,957	113,589,841
Stock Dividend	-	(83,006,000)
Cash Dividend	(18,261,320)	-
Balance carried forward	365,279,757	321,114,120
11.00 Deferred Tax Liabilities		
Opening Balance	118,988,224	101,428,244
Add: Provision made during the period (Note-11.01)	4,567,386	17,559,980
Closing Balance	123,555,610	118,988,224
11.01 Deferred tax liabilities as at December 31, 2021 is arrived as follows :		
Written Down Value of PPE as per Accounting Base	1,207,888,378	1,227,902,159
Written Down Value as per Third Schedule	(658,752,332)	(699,065,607)
Net Temporary Difference	549,136,046	528,836,552
Income Tax Rate	22.50%	22.50%
Deferred Tax Liability	123,555,610	118,988,224
Opening Deferred Tax Liability	(118,988,224)	(101,428,244)
Deferred Tax Expenses	4,567,386	17,559,980
12.00 Unclaimed Dividend Account	3,356,288	6,550,487
Dividend Payable-Previous Year:		
Dividend Payable (2017-2018)	785,248	3,681,708
Dividend Payable (2018-2019)	2,568,956	2,866,695
Dividend Payable (2019-2020)	2,084	2,084
Total	3,356,288	6,550,487
13.00 Dividend Payable:		
Dividend Payable-Current Year:		
Dividend Payable (2020-2021)	18,261,320	-
Total	18,261,320	-
14.00 Liability for Leases net of current Maturity:		
Beginning Balance	607,545	1,141,776
Add: Interest Expenses	21,561	98,269
Less: Payment	(145,000)	(632,500)
Closing Balance	284,106	607,545
Less: Liabilities for lease-current maturity	(284,106)	(607,545)
Total	-	-
15.00 Provision for Current Tax		
Opening Balance	52,411,003	49,369,509
Add: Provision for tax during the period (Note-15.01)	13,556,569	3,041,494
Total	65,967,572	52,411,003
15.01 Provision for Tax during the period		
(A) Regular		
Accounting Profit before Tax	80,550,913	134,191,315
Add: Other Inadmissible Allowances		
Accounting Depreciation	20,124,211	38,168,564
Other Income	(1,217,222)	(11,809,104)
Less: Items for Separate Consideration		
Depreciation as per 3rd Schedule	(40,423,705)	(161,474,538)
Total Taxable Income	59,034,197	(923,763)
Rate	22.50%	22.50%
Total Tax Expenses/Current Tax	13,282,694	(207,847)
Tax on other income	273,875	2,657,048
Total Tax Payable	13,556,569	2,449,201
(B) Minimum Tax		
Revenue from Sales	265,507,813	495,106,639
Other Income	1,217,222	11,809,104
Total Revenue	266,725,035	506,915,743
Rate of Tax	0.60%	0.60%
Minimum Tax	1,600,350	3,041,494
(C) Advance Tax	1,186,484	2,397,065
Provision for the Year (whichever is Higher)	13,556,569	3,041,494



	Amount in Taka		Amount in Taka	
	July 01, 2021 to Dec. 31, 2021	July 01, 2020 to Dec. 31, 2020	Oct 01, 2021 to Dec. 31, 2021	Oct 01, 2020 to Dec. 31, 2020
16.00 Cost of Sales				
Raw Materials Consumed	119,261,010	115,333,107	58,102,337	56,515,628
Manufacturing Overhead (Note-17.00)	33,302,617	30,285,386	16,290,902	15,024,150
	152,563,627	145,618,493	74,393,239	71,539,778
Add: Opening Work in process	10,524,350	14,402,451	13,957,580	13,802,451
Less: Closing Work in process	(9,007,825)	(10,207,825)	(9,007,825)	(10,207,825)
Cost of Goods manufactured	154,080,152	149,813,119	79,342,994	75,134,404
Add: Opening stock of finished Goods	32,626,808	24,923,097	30,675,288	26,225,405
Cost of Goods Available for Sale	186,706,960	174,736,216	110,018,282	101,359,809
Less: Closing stock of finished Goods	(36,527,450)	(36,527,450)	(36,527,450)	(36,527,450)
Less: Sample Distribution	(670,331)	(616,218)	(311,873)	(328,001)
Cost of Sales	149,509,179	137,592,547	73,178,959	64,504,358

17.00 Manufacturing Overhead				
Wages and Salary	5,568,587	4,950,496	2,576,422	2,475,750
Festival Bonus	426,900	238,388	-	-
Overtime	353,013	279,516	111,493	279,516
Packaging Materials Consumed	4,907,657	4,460,169	2,611,022	2,260,918
Spare Parts Consumed	353,953	361,430	175,637	156,750
Repair & Maintenance	197,406	223,821	99,087	60,260
Electricity Bill	711,959	860,579	295,713	404,065
Disel & Fuel	70,500	105,170	40,600	60,970
Electric & Sanitary Goods	87,127	36,026	64,582	19,755
Fire Insurance Premium	96,725	87,050	53,202	43,527
Canteen Expenses	1,010,228	585,744	524,692	235,296
Laboratory Expenses	42,500	14,250	-	-
Cleaning & Washing	52,045	32,755	28,382	16,934
Internet bill	16,760	23,550	9,260	11,550
Mobile & Telephone bill	17,450	18,050	8,550	10,050
Uniform	59,420	68,760	27,000	18,970
Depreciation (Annexure-A)	19,330,387	17,939,632	9,665,260	8,969,839
Total	33,302,617	30,285,386	16,290,902	15,024,150

18.00 Administrative Expenses				
Salary & Allowance	4,598,000	4,126,933	2,402,750	2,063,683
Director Remuneration (Note # 26.01)	600,000	600,000	300,000	300,000
Conveyance	56,555	68,289	24,980	43,254
Subscription, Gift & Donation	242,050	30,910	215,750	13,210
Festival Bonus	299,125	148,375	-	-
Board meeting attendance fees (Note # 26.01)	180,000	180,000	135,000	135,000
Cleaning & Sanitation	38,836	25,239	24,169	13,141
Credit Rating Fee	-	50,000	-	50,000
Electricity Bill	112,660	122,576	46,926	48,977
Entertainment	154,217	112,546	103,550	47,868
Garage Rent	10,800	10,800	5,400	5,400
Legal, License & Renewal & Professional fee	552,081	318,946	226,000	206,641
Research & Product Development	502,900	4,500	502,900	-
Miscellaneous Expense	1,295,461	258,290	827,390	95,850
Newspaper & Magazine	1,370	250	730	250
Postage, Stamps & Courier	8,000	16,124	7,150	10,529
Printing & Stationery	91,144	87,346	49,819	42,730
Office Maintenance	132,030	87,570	75,680	40,035
Vehicle Repair & Maintenance	92,255	31,045	46,550	9,730
Fuel & Gas	284,417	126,252	208,561	70,576
Telephone & Mobile	78,985	99,982	30,000	35,600
Internet bill	54,000	54,000	27,000	27,000
Annual General Meeting Expenses	379,240	48,420	379,240	48,420
Audit Fees Including VAT	115,000	143,750	57,500	57,500
Interest expenses on the Lease Liability	21,561	57,964	8,367	26,840
Depreciation Charge for the Right-of-Use Asset	291,416	291,416	145,708	145,708
Depreciation (Annexure-A)	793,824	804,426	397,515	402,693
Total	10,985,927	7,905,949	6,248,635	3,940,635



19.00 Selling & Marketing Expenses

Salary & Allowance
 Travelling & Conveyance
 Festival Bonus
 Advertisement
 Marketing Promotion
 Distribution Cost
 Sample Distribution
Total

Amount in Taka		Amount in Taka	
July 01, 2021 to Dec. 31, 2021	July 01, 2020 to Dec. 31, 2020	Oct 01, 2021 to Dec. 31, 2021	Oct 01, 2020 to Dec. 31, 2020
8,410,285	6,711,134	4,649,735	3,385,001
1,977,970	1,392,800	1,112,370	647,900
382,485	224,158	-	-
91,742	91,800	82,636	69,000
2,757,311	463,499	1,571,187	255,535
3,776,586	2,722,181	1,992,529	1,096,674
670,331	616,218	311,873	328,001
18,066,710	12,221,790	9,720,330	5,782,111

20.00 Financial Expenses

Bank Charges
 Interest on Loan
 Interest on W.P.P.F Fund Used
Total

232,401	183,752	113,704	167,976
1,598,106	2,316,969	897,850	1,166,323
1,754,254	960,506	877,127	480,253
3,584,761	3,461,227	1,888,681	1,814,552

21.00 Other Income

Interest on FDR
 Bank Interest
 Sales of Wastage
Total

1,050,000	1,700,000	-	-
38,727	33,600	38,727	33,600
128,495	153,592	38,985	87,945
1,217,222	1,887,192	77,712	121,545



22.00 Earnings Per Share**Basic Earnings Per Share:**

Profit after tax

Weighted average number of ordinary shares outstanding (Note: 22.01)

Basic Earnings per share

Half Yearly Product		Quarterly Product	
31-Dec-2021	31-Dec-2020	31-Dec-2021	31-Dec-2020
62,426,957	72,468,904	25,990,923	38,839,891
91,306,600	91,306,600	91,306,600	91,306,600
0.68	0.79	0.28	0.43

As there is no shares under Option, Basic & Diluted earnings per share are same for the period. This has been calculated in compliance with the requirements of IAS 33 Earnings per share. EPS is the basic earnings dividing by the weighted average number of ordinary shares outstanding at the end of the period.

22.01 Calculation of Weighted Average Number of Shares as on December 31, 2021

Particulars	Share Numbers	Outstanding Period	Length in Days	Daily Product	Half Yearly Product (Weighted Average)	Quarterly Product (Weighted Average)
					31-Dec-2021	31-Dec-2020
Shares at beginning	91,306,600	July-21 to Dec-21	184	16,800,414,400	91,306,600	91,306,600
Total	91,306,600			16,800,414,400	91,306,600	91,306,600

23.00 Net Asset Value (NAV) per Share

Total Asset

Less: Total outside Liability

Net Asset

Number of ordinary shares outstanding

Net Assets Value (NAV) per Share

31-Dec-2021	30-Jun-2021
1,593,031,677	1,520,042,745
314,685,920	285,862,625
1,278,345,757	1,234,180,120
91,306,600	91,306,600
14.00	13.52

24.00 Net Operating Cash Flows per Share(NOCFPS)

Net Cash Generated From Operating Activities

Weighting Average Number of Shares Outstanding

Net Operating Cash Flows per Share(NOCFPS)

31-Dec-2021	31-Dec-2020
96,093,998	117,216,015
91,306,600	91,306,600
1.05	1.28

25.00 Reconciliation of Net Profit with cash flows from Operating Activities:**Profit before Tax**

Adjustment for:

Depreciation on property, plant and equipment

Adjustment for depreciation of the Right Use of Assets

Interest expenses on Lease

Financial Expenses

(Increase)/Decrease in Accounts Receivable

(Increase)/Decrease in Inventory

Less: Increase/(Decrease) in Trade and Other Payables

Add: Decrease/(Increase) in Advance, Deposit & Prepayments

Add: Increase in Liabilities for Expenses

Add: Increase in Liability for contribution to W P P F

Less: Income Tax Paid

Net Cash Generated from Operating Activities

31-Dec-2021	31-Dec-2020
80,550,913	97,741,647
20,124,211	18,744,058
291,416	291,416
21,561	57,964
3,584,761	3,461,227
104,572,862	120,296,312
(2,899,565)	9,110,433
(1,784,001)	(9,386,430)
(4,530,774)	(523,164)
(81,586)	(4,435,323)
(2,023,999)	(2,003,314)
4,027,546	4,887,082
97,280,482	117,945,596
(1,186,484)	(729,581)
96,093,998	117,216,015



26.00 Related parties Transaction:

As per IAS 24 Related Party Disclosures, Parties are considered to be related if one of the party has the ability to control the other party or exercise significant influence over the other party in making financial and operating decision.

26.01 As per paragraph 17 of IAS 24 : Disclosure of key management personnel compensation.**a) Short-term employee benefits :**

The amount of transaction for remuneration and board meeting fee during the period from 1st July 2021 to 31 st December 2021 are as follows:

Name	Designation	Remuneration	Board meeting fee
Asif Iqbal Chowdhury	Chairman	-	20,000
Faria Binta Alam	Managing Director	600,000	20,000
Wajhi Ahmed	Director	-	20,000
Kazi Rina Alam	Director	-	20,000
Md. Tazul Islam	Director	-	20,000
Mohammad Towhidul Islam	Nominee Director	-	20,000
Dr. Khandaker Sagir Ahmed	Nominee Director	-	20,000
Mohammed Salim	Independent Director	-	20,000
Shekh Karimuzzaman	Independent Director	-	20,000
Total		600,000	180,000

b) Post employment benefits: Nil

c) Other long term benefits: Nil

d) Termination benefits: Nil

e) Share-based payment: Nil

27.00 Significant Deviation

Advent Pharma Ltd. is a veterinary medicine producer. During the period our sales has increased slightly comparative to previous period and increased operating expenses also. As a result net profit after tax and earnings per share has decreased and net operating cash flow per share has decreased due to increase of accounts receivable comparative to previous period and also increase of cash paid to suppliers, employees, others and income tax payment proportionately from the previous period.



Advent Pharma Ltd.
Schedule of Property, Plant and Equipment
As at December 31, 2021

Annexure-A
(Amount in Taka)

Particulars	Cost				Rate of Dep.	Depreciation			Written down value as on 31-Dec-2021
	Balance as on 01-July-2021	Addition during the Period	Disposal during the Period	Balance as on 31-Dec-2021		Charged during the Period	Adjustment during the Period	Balance as on 31-Dec-2021	
Land	3,783,816	-	-	3,783,816	0%	-	-	-	3,783,816
Land Development	9,454,530	-	-	9,454,530	2.5%	1,017,385	105,464	-	8,331,681
Factory Building	925,159,750	-	-	925,159,750	2.5%	53,242,607	10,898,964	-	861,018,179
Plant & Machinery	273,073,384	10,750	-	273,084,134	5%	55,257,423	5,445,533	-	212,381,178
Sub-Station	6,694,722	-	-	6,694,722	10%	3,105,131	179,480	-	3,410,111
Motor Vehicle	6,158,982	-	-	6,158,982	15%	2,754,098	255,366	-	3,009,464
Furniture & Fixture	8,126,555	33,780	-	8,160,335	10%	3,006,215	256,821	-	3,149,518
Solar Panel	2,004,740	-	-	2,004,740	10%	885,455	55,964	-	4,897,299
Generator	627,520	-	-	627,520	10%	366,147	13,069	-	1,063,321
Air Conditioner	4,254,120	-	-	4,254,120	5%	1,053,265	80,021	-	248,304
Office Equipment	6,501,413	65,900	-	6,567,313	10%	2,481,538	201,616	-	3,120,834
HVAC System	44,536,240	-	-	44,536,240	5%	9,923,800	865,311	-	3,884,159
Laboratory Equipment	51,378,630	-	-	51,378,630	5%	11,374,138	1,000,112	-	33,747,129
Product Development Equipment	20,725,781	-	-	20,725,781	5%	4,564,653	404,028	-	39,004,380
ETP	18,488,470	-	-	18,488,470	5%	4,056,954	360,788	-	15,757,100
Books & Journals	45,000	-	-	45,000	15%	22,685	1,674	-	14,070,728
Total	1,381,013,653	110,430	-	1,381,124,083		153,111,494	20,124,211	-	20,641
									1,207,888,378

Allocation of Depreciation:

Administrative cost	793,824
Factory cost	19,330,387
Total	20,124,211



Advent Pharma Ltd.
Schedule of Property, Plant and Equipment
As at December 31, 2020

Particulars	Cost			Rate of Dep.	Depreciation			Written down value as on 31-Dec.-2020
	Balance as on 01-July-2020	Addition during the period	Disposal during the period		Balance as on 01-July-2020	Charged during the period	Adjustment during the period	
Land	3,783,816	-	-	0%	-	-	-	3,783,816
Land Development	9,454,530	-	-	2.5%	801,048	108,169	-	8,545,313
Factory Building	758,842,294	-	-	2.5%	34,439,549	9,055,034	-	715,347,711
Plant & Machinery	273,035,384	-	-	5%	43,794,758	5,731,016	-	223,509,610
Sub-Station	6,694,722	-	-	10%	2,706,287	199,422	-	3,789,013
Motor Vehicle	6,097,576	-	-	15%	3,195,020	217,692	-	2,684,864
Furniture & Fixture	8,059,885	50,920	-	10%	2,439,835	282,700	-	5,388,270
Solar Panel	2,004,740	-	-	10%	761,090	62,183	-	1,181,467
Generator	627,520	-	-	10%	337,106	14,521	-	275,893
Air Conditioner	4,254,120	-	-	5%	884,799	84,233	-	3,285,088
Office Equipment	6,431,313	13,500	-	10%	2,041,010	219,801	-	4,184,002
HVAC System	44,536,240	-	-	5%	8,102,093	910,854	-	35,523,293
Laboratory Equipment	51,322,810	4,800	-	5%	9,270,247	1,051,394	-	41,005,969
Product Development Equipment	20,725,781	-	-	5%	3,714,067	425,293	-	16,586,421
ETP	18,488,470	-	-	5%	3,297,400	379,777	-	14,811,293
Books & Journals	45,000	-	-	15%	18,747	1,969	-	24,284
Total	1,214,404,201	69,220	-		115,803,056	18,744,058	-	1,079,926,307

Allocation of Depreciation:

Administrative cost	804,426
Factory cost	17,939,632
Total	18,744,058

